Join Our Community

Traditional Medications for Diabetes

Oral Antidiabetic Agents

Oral antidiabetic agents have been used to treat type 2 diabetes since the 1950s. The first oral drug approved for the treatment of diabetes was tolbutamide, which was introduced in 1957. Since then, many other classes of oral antidiabetic agents have been developed, including sulfonylureas, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors. Oral antidiabetic agents work by improving the body’s ability to produce insulin or by increasing the sensitivity of cells to insulin. This can help to lower blood sugar levels and improve glycemic control in people with type 2 diabetes. However, it is important to note that oral antidiabetic agents are not a cure for type 2 diabetes. They are used to manage the condition and help to prevent complications. The choice of oral antidiabetic agent will depend on a number of factors, including the severity of the diabetes, the patient’s overall health, and the presence of other medical conditions. Some oral antidiabetic agents are more effective than others in certain situations. For example, metformin is often the first choice of treatment for people with type 2 diabetes because it is effective, safe, and relatively inexpensive. However, other oral antidiabetic agents may be more appropriate for patients who do not respond to metformin or who have other medical conditions.
Metformin (Glucophage)

Metformin, a biguanide, is one of the most commonly prescribed oral antidiabetic agents due to its efficacy and safety profile. It primarily works by reducing glucose production in the liver, thereby lowering blood sugar levels. Additionally, metformin has been shown to improve insulin sensitivity in peripheral tissues, such as muscle and fat. This dual mechanism of action contributes to its effectiveness in managing type 2 diabetes.
Beyond its glucose-lowering effects, metformin has several other benefits. It has been associated with a reduced risk of cardiovascular disease, including heart attack and stroke, in people with type 2 diabetes. This protective effect may be related to its ability to improve lipid profiles, reduce blood pressure, and decrease inflammation. Furthermore, metformin may have weight-loss properties, which can be beneficial for individuals with type 2 diabetes, as obesity is a significant risk factor for the condition.

While metformin is generally well-tolerated, it can cause gastrointestinal side effects such as diarrhea, nausea, and abdominal pain. These side effects often resolve within a few weeks of starting the medication. In rare cases, metformin can cause lactic acidosis, a serious condition characterized by excessive lactic acid buildup in the blood. This risk is particularly high in individuals with kidney disease or liver dysfunction. Therefore, it is important to monitor kidney function and liver enzymes regularly in patients taking metformin.

Sulfonylureas (Glyburide, Glipizide, Glimepiride)

Sulfonylureas, a class of oral antidiabetic medications, work by stimulating the pancreas to produce more insulin. They are effective in patients who still have some insulin-producing capacity, but they may not be as effective in patients with severe insulin deficiency.
The mechanism of action of sulfonylureas involves the binding to and activation of ATP-sensitive potassium channels in pancreatic beta cells. This activation leads to the closure of these channels, which depolarizes the beta cells and triggers the release of insulin. By increasing insulin secretion, sulfonylureas can help to lower blood sugar levels and improve glycemic control in patients with type 2 diabetes.

However, sulfonylureas can also have some potential drawbacks. One of the main concerns with sulfonylurea use is the risk of hypoglycemia, or low blood sugar. This can occur if the dosage is too high, if meals are missed or delayed, or if the patient engages in strenuous exercise. Symptoms of hypoglycemia can include sweating, shaking, dizziness, and confusion. If left untreated, hypoglycemia can lead to more serious complications, such as seizures or coma.

Another potential side effect of sulfonylureas is weight gain. This can be a concern for patients with type 2 diabetes, as obesity is a risk factor for the condition. The weight gain associated with sulfonylurea use is thought to be related to the increased insulin levels.

In addition to hypoglycemia and weight gain, sulfonylureas can also cause gastrointestinal side effects, such as nausea, vomiting, and diarrhea. These side effects are usually mild and often resolve on their own. However, if they become severe or persistent, it may be necessary to discontinue the medication.

Overall, sulfonylureas can be effective medications for managing type 2 diabetes. However, it is important to weigh the benefits and risks of these medications with your healthcare provider. If you are prescribed a sulfonylurea, it is important to monitor your blood sugar levels closely and to be aware of the signs and symptoms of hypoglycemia.

Thiazolidinediones (TZDs) (Pioglitazone, Rosiglitazone)

Thiazolidinediones (TZDs) are a class of oral antidiabetic medications that work by improving insulin sensitivity in target tissues, such as the liver and muscle. This means that they help the body's cells respond more effectively to insulin, leading to lower blood sugar levels. TZDs are particularly effective in patients who are resistant to insulin, meaning their cells are not responding to insulin as they should.
However, TZDs are associated with some potential side effects. One of the most serious side effects is an increased risk of heart failure. This risk is particularly high in patients who already have heart problems or who are taking other medications that can increase the risk of heart failure. Another potential side effect of TZDs is an increased risk of bladder cancer. This risk is relatively low, but it is important to discuss it with your healthcare provider if you are considering taking a TZD.

In addition to heart failure and bladder cancer, TZDs can also cause weight gain and fluid retention. This can be a concern for patients with type 2 diabetes, as obesity is a risk factor for the condition. The weight gain associated with TZD use is thought to be related to the increased insulin sensitivity.

Overall, TZDs can be effective medications for managing type 2 diabetes, but it is important to weigh the benefits and risks with your healthcare provider. If you are prescribed a TZD, it is important to monitor your blood sugar levels closely and to be aware of the signs and symptoms of heart failure and bladder cancer.

DPP-4 Inhibitors (Sitagliptin, Saxagliptin, Linagliptin)

DPP-4 inhibitors are a class of oral antidiabetic medications that work by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). DPP-4 is responsible for breaking down incretin hormones, which are released from the intestines in response to meals. Incretin hormones stimulate the pancreas to produce insulin and slow down the emptying of the stomach, helping to regulate blood sugar levels after eating.
By inhibiting DPP-4, these medications increase the levels of incretin hormones in the body, leading to improved glycemic control. DPP-4 inhibitors are generally well-tolerated, with a low risk of hypoglycemia. Common side effects include upper respiratory tract infections, headache, and nasopharyngitis. However, in rare cases, DPP-4 inhibitors can cause pancreatitis, a serious condition that affects the pancreas.

In addition to their glucose-lowering effects, DPP-4 inhibitors may also have other benefits for people with type 2 diabetes. Some studies have suggested that these medications may help to reduce the risk of cardiovascular disease and improve kidney function. However, more research is needed to confirm these potential benefits.

Alpha-glucosidase inhibitors (Acarbose, Miglitol)

Alpha-glucosidase inhibitors are a class of oral antidiabetic medications that work by slowing down the absorption of carbohydrates from the intestines. This can help to lower blood sugar levels after meals. By delaying the breakdown of carbohydrates into glucose, these medications can reduce the rate at which blood sugar rises after a meal.
Alpha-glucosidase inhibitors are particularly effective in patients who have difficulty controlling their blood sugar levels after meals. They can also be used in combination with other antidiabetic medications, such as metformin or insulin.

However, alpha-glucosidase inhibitors can cause gastrointestinal side effects, such as flatulence, diarrhea, and abdominal bloating. These side effects are often mild and may improve over time. In some cases, however, they can be severe enough to interfere with a person's daily life.

If you are considering taking alpha-glucosidase inhibitors, it is important to discuss the potential benefits and risks with your healthcare provider. They can help you determine if these medications are right for you and can monitor you for any side effects.

GLP-1 Medications: A Brief Overview

GLP-1 receptor agonists are a class of prescription medications used to treat type 2 diabetes and, in some cases, obesity. They work by mimicking a natural hormone that stimulates insulin release when blood sugar rises, reduces glucagon production, slows stomach emptying, and increases feelings of fullness. These combined effects help lower blood glucose, reduce appetite, promote weight loss, and may lower the risk of heart disease and kidney complications in appropriate patients. Some medications in this class have also demonstrated cardiovascular and kidney protection beyond glucose control.

Insulin can be made from a variety of sources, including:

1

Ozempic® (Semaglutide)

Ozempic is a once-weekly injectable medication approved for adults with type 2 diabetes. In addition to lowering A1C, it has been shown to reduce the risk of major cardiovascular events in certain patients with diabetes and cardiovascular disease.

2

Wegovy® (Semaglutide)
Wegovy contains the same active ingredient as Ozempic but is approved for chronic weight management in people who meet specific medical criteria. It uses higher maintenance doses and is intended to be combined with healthy eating and regular physical activity.

3

Mounjaro® (Tirzepatide)

Mounjaro is a once-weekly injectable medication approved for type 2 diabetes. Unlike semaglutide, tirzepatide activates both GLP-1 and GIP receptors, providing powerful blood sugar control while also promoting significant weight loss.

4

Zepbound® (Tirzepatide)
Zepbound contains the same active ingredient as Mounjaro but is approved specifically for chronic weight management. It combines lifestyle changes with medication to help individuals achieve and maintain substantial weight loss.

Additional Medications and Practical Guidance

Eating Recommendations
Most healthcare providers recommend eating smaller meals, emphasizing lean protein, vegetables, and high-fiber foods while limiting greasy or high-fat meals during the first several weeks of treatment. Staying well hydrated and eating slowly can also help reduce digestive side effects.
Common Adverse Effects
The most frequently reported side effects include nausea, constipation, diarrhea, vomiting, stomach discomfort, and early fullness. These symptoms often improve as the body adjusts, although serious complications such as pancreatitis, gallbladder disease, or severe dehydration require prompt medical attention. Patients should also obtain these medications only through licensed pharmacies because unapproved compounded products may carry additional risks.
Cost Considerations
Without insurance, GLP-1 medications can cost hundreds to over $1,000 per month. Insurance coverage, prior authorization requirements, manufacturer savings programs, and prescription assistance may significantly reduce out-of-pocket costs for eligible patients.
Personal Adjustments

Successful treatment often requires adopting long-term lifestyle changes. Patients should prioritize adequate protein intake, regular physical activity—especially resistance training—good hydration, routine blood glucose monitoring, and consistent follow-up with their healthcare team. Because appetite decreases substantially for many people, learning to recognize fullness and maintaining balanced nutrition become important parts of long-term success.

Insulin

Insulin is a hormone produced by the pancreas that helps to regulate blood sugar levels. People with type 1 diabetes and many people with type 2 diabetes require insulin therapy to manage their blood sugar. Insulin is a protein that is produced by specialized cells in the pancreas called beta cells. It is released into the bloodstream in response to rising blood sugar levels.
Insulin works by binding to receptors on cells throughout the body, which allows glucose to enter the cells and be used for energy.
Insulin can be made from a variety of sources, including:

1

Human insulin
This is insulin that is produced by genetically engineered bacteria or yeast. It is the most common type of insulin used today

2

Animal insulin
This is insulin that is extracted from the pancreas of animals, such as pigs or cows. It is less common today than human insulin, but it is still used in some parts of the world.

3

Recombinant human insulin
This is insulin that is produced by genetically engineered bacteria or yeast using human insulin DNA. It is identical to human insulin produced by the pancreas.
Insulin is available in a variety of different formulations, including:
Rapid-acting insulin (Lispro, Aspart, Glulisine)
This type of insulin starts working within 15 minutes and peaks within 1-2 hours. It is often used to cover meals or to correct high blood sugar levels.
Short-acting insulin (Regular Insulin)
Similar to rapid-acting insulin, short-acting insulin starts working within 30 minutes and peaks within 2-4 hours. It is often used in combination with intermediate-acting or long-acting insulin.
Intermediate-acting insulin (NPH Insulin)
This type of insulin starts working within 1-2 hours and peaks within 6-12 hours. It is often used in combination with rapid-acting insulin to provide both basal and prandial coverage.
Long-acting insulin (Glargine, Detemir)

These insulins provide a steady baseline level of insulin throughout the day. They can be used once or twice daily.

Insulin is administered by injection, either with a syringe or an insulin pen. Common side effects of insulin therapy include hypoglycemia, injection site reactions, and allergic reactions. Hypoglycemia, or low blood sugar, is a common side effect of insulin therapy. It can occur if the insulin dosage is too high, if meals are missed or delayed, or if the patient engages in strenuous exercise. Symptoms of hypoglycemia can include sweating, shaking, dizziness, and confusion. If left untreated, hypoglycemia can lead to more serious complications, such as seizures or coma.

Injection site reactions are another common side effect of insulin therapy. These reactions can include redness, swelling, itching, or pain at the injection site. They are often mild and may resolve on their own. However, if injection site reactions become severe or persistent, it may be necessary to change the injection site or type of insulin.

Allergic reactions to insulin are rare but can be life-threatening. Symptoms of an allergic reaction can include hives, swelling, difficulty breathing, and a rapid heartbeat. If you experience an allergic reaction to insulin, seek medical attention immediately.